Non-GAAP altered net gain for the first quarter of 2014 was $18.4 million, or $0.16 per diluted share, compared to non-GAAP adjusted net income of $14.4 million, or $0.13 per diluted talk about, in the last year quarter. 2014 Up to date Outlook The Company's previous guidance assumed that Akorn would acquire Hi-Tech effective April 1, 2014. However, until April 17 the acquisition was not completed, 2014. While Akorn and Hi-Tech now have over 73 ANDAs on file with the FDA, this guidance will not are the impact of any potential new product approvals given the timing uncertainty of the regulatory acceptance process.Norway has a malignancy registry also, enabling the researchers to recognize blood samples of individuals who developed a human brain tumor. The blood samples were collected an average of 15 years before tumors were detected. Particularly, the researchers compared interactions between 12 allergy-related proteins, called cytokines, in the blood samples of 487 people identified as having glioma and 487 samples from people without cancer. Cytokines are activated during an allergy-related immune response. Allergies, the study authors noted, have been associated with decreased risk for glioma.